USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Mar 16, 2022 (est) | Dec 31, 2021 | - | $-0.14 | $-0.04 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Mar 16, 2022 (est) | Dec 31, 2021 | - | $0.00 | $0.00 |
Hoth Therapeutics's next estimated earnings date (based on same quarter last year's date) is Mar 16, 2022 for the fiscal quarter ending Dec 31, 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 3 | $-0.57 | $-0.61 | $-0.55 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 0 / 0 | $-0.57 | $-0.60 | $-0.60 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 2 | $0.00 | $0.00 | $0.00 |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Nov 10, 2021 | Sep 2021 | $-0.12 | $-0.14 | -16.67% |
| Aug 11, 2021 | Jun 2021 | $-0.17 | $-0.14 | 17.65% |
| May 13, 2021 | Mar 2021 | $-0.10 | $-0.24 | -140.00% |
| Mar 16, 2021 | Dec 2020 | $-0.10 | $-0.04 | 60.00% |
| Nov 10, 2020 | Sep 2020 | $-0.14 | $-0.16 | -18.52% |
| Aug 13, 2020 | Jun 2020 | $-0.14 | $-0.20 | -48.15% |
| May 13, 2020 | Mar 2020 | $-0.17 | $-0.18 | -7.98% |
| Mar 2, 2020 | Dec 2019 | $-0.14 | $-0.41 | -199.93% |
| Nov 12, 2019 | Sep 2019 | $-0.10 | $-0.17 | -64.57% |
| Aug 14, 2019 | Jun 2019 | $-0.11 | $-0.13 | -18.18% |
| Apr 1, 2019 | Mar 2019 | - | $-0.12 | - |
| Mar 31, 2019 | Dec 2018 | - | $-0.06 | - |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 16, 2021 | Dec 2020 | $-0.63 | $-0.58 | - |
| Mar 2, 2020 | Dec 2019 | $-0.53 | $-0.83 | - |
| Mar 31, 2019 | Dec 2018 | - | $-0.06 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Nov 10, 2021 | Sep 2021 | $0.00 | $0.00 | - |
| Aug 11, 2021 | Jun 2021 | $0.00 | $0.00 | - |
| May 13, 2021 | Mar 2021 | $0.00 | $0.00 | - |
| Mar 16, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Nov 10, 2020 | Sep 2020 | $0.00 | $0.00 | - |
| Aug 13, 2020 | Jun 2020 | $0.00 | $0.00 | - |
| May 13, 2020 | Mar 2020 | $0.00 | $0.00 | - |
| Mar 2, 2020 | Dec 2019 | $0.00 | $0.00 | - |
| Nov 12, 2019 | Sep 2019 | $0.00 | $0.00 | - |
| Aug 14, 2019 | Jun 2019 | $0.00 | $0.00 | - |
| Apr 1, 2019 | Mar 2019 | - | $0.00 | - |
| Mar 31, 2019 | Dec 2018 | - | $0.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 16, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Mar 2, 2020 | Dec 2019 | $0.00 | $0.00 | - |
| Mar 31, 2019 | Dec 2018 | - | $0.00 | - |
HOTH's next estimated earnings date (based on same quarter last year's report date) is Mar 16, 2022 for the fiscal quarter ending Dec 31, 2021.
Hoth Therapeutics's previous earnings date was Nov 10, 2021 for its fiscal quarter ended Sep 30, 2021.
HOTH's earnings per share (EPS) was $-0.14, missing the consensus analysts forecast of $-0.12 by -16.67%.
The EPS was higher than the previous fiscal quarter (Jun 2021) by 0.00%, and higher than the same period a year before (Sep 2020) by -12.50%.
Revenues were $0.00.
The company reported a net income of $-3.30M.Free cash flow for the quarter was $-2.79M , compared to $-2.70M last quarter and $-1.53M a year before.
Hoth Therapeutics's previous annual earnings date was Mar 16, 2021 for its fiscal year ended Dec 31, 2020.
HOTH's earnings per share (EPS) was $-0.58, beating the consensus analysts forecast of $-0.63 by -7.94% , and higher than the previous year's EPS (Dec 2019) by -29.99%.
Revenues were $0.00.
The company reported a net income of $-7.20M.
Hoth Therapeutics reported a free cash flow of $-6.30M for its fiscal year, compared to $-5.04M a year ago.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
